Impact of Neoadjuvant Docetaxel, Cisplatin, and 5‐Fluorouracil Therapy on Synchronous Early‐Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer
Head & Neck · 2026
DOI: 10.1002/hed.70326 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2026. Verfasst von Tatsuya Ito und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Hypopharyngeal Neoplasms. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science (JSPS) KAKENHI, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
To evaluate the therapeutic effect of neoadjuvant docetaxel, cisplatin, and 5‐fluorouracil (NeoDCF), the standard treatment for stage IB–III esophageal squamous cell carcinoma (ESCC), against synchronous superficial pharyngeal squamous cell carcinoma (PSCC).
Methods
We retrospectively reviewed ESCC patients with synchronous early‐stage PSCC who received NeoDCF. The primary endpoint was disease‐specific survival (DSS) for PSCC. Secondary endpoints included overall survival (OS), local tumor response, and time to progression (TTP) of PSCC.
Results
Among 786 patients with ESCC, 58 (7.4%) had synchronous early‐stage PSCC. Local tumor response was complete disappearance in 33 (57%) patients, partial reduction in 24 (41%), and no change in 1 (2%). The 3‐year DSS, OS, and TTP were 100%, 61%, and 78%, respectively. No significant difference was found between the Tis and T1/T2 groups ( p = 0.67).
Conclusions
NeoDCF demonstrated excellent efficacy against early‐stage PSCC, supporting prioritization of ESCC treatment with timely local intervention for recurrent PSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck Surgery, National Cancer Center Hospital, Tokyo, Japan.
- Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
ORCID-Profile: Tatsuya Ito, Go Omura, Toshihiko Sakai, Azusa Sakai, Kohtaro Eguchi, Takane Watanabe, Akihisa Tanaka, Mitsuhiko Katoh, Yoshitaka Honma, Hideaki Takahashi, Ken Kato, Seiichi Yoshimoto
Förderung
- Japan Society for the Promotion of Science (JSPS) KAKENHI
- Japan Society for the Promotion of Science
Zitieren
APA
Ito, T., Omura, G., Fushimi, C., Sakai, T., Sakai, A., Eguchi, K., Hayashi, T., Watanabe, T., Tanaka, A., Katoh, M., Imazeki, H., Yamamoto, S., Honma, Y., Takahashi, H., Kato, K., & Yoshimoto, S. (2026). Impact of Neoadjuvant Docetaxel, Cisplatin, and 5‐Fluorouracil Therapy on Synchronous Early‐Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer. Head & Neck. https://doi.org/10.1002/hed.70326
Vancouver
Ito T, Omura G, Fushimi C, Sakai T, Sakai A, Eguchi K, et al. Impact of Neoadjuvant Docetaxel, Cisplatin, and 5‐Fluorouracil Therapy on Synchronous Early‐Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer. Head & Neck. 2026. doi:10.1002/hed.70326
BibTeX
@article{Ito2026,
author = {Ito, Tatsuya and Omura, Go and Fushimi, Chihiro and Sakai, Toshihiko and Sakai, Azusa and Eguchi, Kohtaro and Hayashi, Takaaki and Watanabe, Takane and Tanaka, Akihisa and Katoh, Mitsuhiko and Imazeki, Hiroshi and Yamamoto, Shun and Honma, Yoshitaka and Takahashi, Hideaki and Kato, Ken and Yoshimoto, Seiichi},
title = {Impact of Neoadjuvant Docetaxel, Cisplatin, and 5‐Fluorouracil Therapy on Synchronous Early‐Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer},
journal = {Head & Neck},
year = {2026},
doi = {10.1002/hed.70326}
}
EUVIMED